Sponsor · clinical trials

Nanjing First Hospital, Nanjing Medical University clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China and Japan registers with Nanjing First Hospital, Nanjing Medical University as lead sponsor. Synced 10 Nov 2026

74Current trials

44Recruiting now

30Drugs in these trials

2Trial registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Synced 10 Nov 2026 · Editorial standards

At a glance

Nanjing First Hospital, Nanjing Medical University is the lead sponsor of 74 current clinical trials in our China and Japan registers. 44 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are GDMT, Recombinant Human Thyroid Stimulating Hormone and Tirzepatide. The most-studied condition is Coronary Artery Disease.

ClinicalTrials.gov trials by status

Recruiting4459%
Not yet open1824%
Active, closed1115%
By invitation11%

Trials by phase

Not applicable3547%
Observational2939%
Phase 479%
Phase 334%

Clinical trials sponsored by Nanjing First Hospital, Nanjing Medical University

74 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Gut Microbiota and Prognostic Outcomes in Intracranial Arterial Stenosis Patients（GROW-ICAS） NCT07085299 · ClinicalTrials.gov ↗ · Intracranial Artery Stenosis	Observational	Recruiting	2025-06	China
Efficacy of Bioceramic Materials for Bone Defects Repair NCT06249906 · ClinicalTrials.gov ↗ · Bone Lesion, Cartilage Degeneration, Osteo Arthritis Knee	Not applicable	Recruiting	2024-02	China
Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma NCT07195500 · ClinicalTrials.gov ↗ · Neuroblastoma, Pheochromocytoma, Paraganglioma	Observational	Recruiting	2024-12	China
Different Treatment Strategies on Prognosis of Acute Ischemic Stroke(AISDTS) NCT05410457 · ClinicalTrials.gov ↗ · Ischemic Stroke	Observational	Recruiting	2022-05	China
18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis NCT06937112 · ClinicalTrials.gov ↗ · Lung Cancers, Pancreatic Cancer, Neuroendocrine Tumors	Observational	Recruiting	2025-04	China
Laser-assisted Ultrasound-guided Peripheral Vein Cannulation in Cardiac Surgery NCT07079904 · ClinicalTrials.gov ↗ · Ultrasonography, Interventional	Not applicable	Recruiting	2025-07	China
Circulating Non-coding RNA in Acute Ischemic Stroke (AISRNA) NCT04175691 · ClinicalTrials.gov ↗ · Acute Stroke, Ischemic Stroke	Observational	Recruiting	2019-11	China
Super High-pressure Balloon Versus Intravascular Lithotripsy to Prepare Severely Calcified Coronary Lesions NCT07093788 · ClinicalTrials.gov ↗ · PCI, Coronary Arterial Disease (CAD), Calcified Coronary Lesions	Not applicable	Recruiting	2025-09	China
Keverprazan-Minocycline Dual Therapy of Different Durations Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication. NCT07904429 · ClinicalTrials.gov ↗ · Helicobacter Infection Drugs: Amoxicillin, Keverprazan, Minocycline	Phase 3	Recruiting	2026-07	China
National Registry and Cohort Study of Pulmonary Vascular Disease NCT05368467 · ClinicalTrials.gov ↗ · Pulmonary Arterial Hypertension	Observational	Recruiting	2022-03	China, Japan
Effect of Percutaneous Electrical Acupoint Stimulation on the Improvement of Incidence of Adverse Respiratory Events NCT06772961 · ClinicalTrials.gov ↗ · Extubation, Respiratory Depression, Acupuncture Points	Not applicable	Recruiting	2025-01	China
Colchicine Treatment for Non-Flow-Limiting Coronary Plaque by Coronary CTA: A Randomized Controlled Trial NCT07349875 · ClinicalTrials.gov ↗ · Coronary Artery Disease (CAD) Drug: Colchicine	Phase 4	Recruiting	2026-01	China
IVUS-guided DES Implantation in Coronary Calcification NCT05800002 · ClinicalTrials.gov ↗ · Coronary Artery Disease	Not applicable	Recruiting	2023-04	China
The Impact of Ultrasound-Guided Superficial and Deep Paravertebral Nerve Blocks at the Superior Costotransverse Ligament on Hemodynamics During the Induction Phase of Thoracoscopic Lung Lobectomy: A Multicenter, Double-Blind, Randomized Controlled Trial NCT06841822 · ClinicalTrials.gov ↗ · Thoracic Paravertebral Block, Anesthesia Induction, Hypotension on Induction	Not applicable	Recruiting	2025-05	China
68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor Diagnosis NCT07914764 · ClinicalTrials.gov ↗ · Medullary Thyroid Carcinoma, Small Cell Lung Cancer ( SCLC ), Gastric Adenocarcinoma	Observational	Recruiting	2026-08	China
Local Anaesthetic Spread and Sensory Block Range of the Retro-superior Costotransverse Ligament Space Block NCT07153263 · ClinicalTrials.gov ↗ · Pulmonary Nodules, Nerve Block	Not applicable	Recruiting	2025-09	China
IVI-guided Versus Angiography-guided PCI in Patients With Diabetes Mellitus NCT06380868 · ClinicalTrials.gov ↗ · Diabetes	Not applicable	Recruiting	2024-07	China
Effect of Subanesthetic Dose of Esketamine on Sleep Quality NCT06773143 · ClinicalTrials.gov ↗ · Insomnia, Breast Cancer Surgery, Esketamine Drug: Esketamine	Not applicable	Recruiting	2024-12	China
Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment NCT06405217 · ClinicalTrials.gov ↗ · DTC - Differentiated Thyroid Cancer, Thyroid Stimulating; Hormone, C, Radiotherapy; Complications Drug: Recombinant Human Thyroid Stimulating Hormone	Not applicable	Recruiting	2024-04	China
Progression, Management, and Clinical Outcomes of Coronary Artery Aneurysms NCT07764081 · ClinicalTrials.gov ↗ · Coronary Artery Disease, Aneurysms, Coronary Intervention	Observational	Recruiting	2026-07	China
Intravascular Imaging-Guided Versus Angiography- Guided PCI in Patients With DES-ISR NCT07297641 · ClinicalTrials.gov ↗ · PCI, In-stent Restenosis, Intravascular Imaging Device	Observational	Recruiting	2026-01	China
Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes NCT05553093 · ClinicalTrials.gov ↗ · Type 2 Diabetes Mellitus Drugs: Insulin glargine, Tirzepatide	Phase 4	Recruiting	2022-03	China
Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma NCT07064746 · ClinicalTrials.gov ↗ · Neuroblastoma (NB)	Observational	Recruiting	2022-07	China
Impact of Procedural Factors on Drug-Coated Balloon Outcomes in Coronary Artery Disease NCT07764094 · ClinicalTrials.gov ↗ · PCI, Drug-coated Balloon, Coronary Artery Disease	Observational	Recruiting	2026-09	China
Eradication of Helicobacter Pylori Improves Metabolic Syndrome Through Modulation of Gut Microbiota. NCT07306988 · ClinicalTrials.gov ↗ · HELICOBACTER PYLORI INFECTIONS, Metabolic Syndrome	Phase 4	Recruiting	2025-04	China
Current Status of Islet Alpha Cell Function in Patients with Type 2 Diabetes NCT06825182 · ClinicalTrials.gov ↗ · Type 2 Diabetes Mellitus	Phase 3	Recruiting	2024-11	China
Nasopharyngeal Airway Combined With Nasal High-flow Oxygen Therapy During Painless Gastroscopy in Obesity Patients NCT06966934 · ClinicalTrials.gov ↗ · Hypoxia, Obesity, Gastrostomy	Not applicable	Recruiting	2025-05	China
Coronary and Myocardial Evaluation by Cardiac CT for Acute Myocardial Infarction NCT07537296 · ClinicalTrials.gov ↗ · Acute Myocardial Infarction (AMI)	Observational	Recruiting	2026-01	China
Different Injection Speed on Local Anaesthetic Spread of ESPB NCT06936904 · ClinicalTrials.gov ↗ · Erector Spinae Plane Block	Not applicable	Recruiting	2025-04	China
Drug-coating Balloon Treatment in Coronary Artery Disease NCT04255563 · ClinicalTrials.gov ↗ · Coronary Artery Disease	Observational	Recruiting	2020-02	China
Effects of Inclisiran Combined With Statins on the Morphology of Coronary Vulnerable Plaques NCT06338293 · ClinicalTrials.gov ↗ · Coronary Artery Disease Drugs: Inclisiran sodium, Rosuvastatin	Phase 4	Recruiting	2024-03	China
Safety and Efficacy of Recombinant Human Thyroid Stimulating Hormone for Adjuvant Diagnosis in Patients With Locally Advanced/Metastatic Differentiated Thyroid Cancer NCT06431620 · ClinicalTrials.gov ↗ · Recombinant Human Thyroid Stimulating Hormone Drug: Recombinant Human Thyroid Stimulating Hormone	Not applicable	Recruiting	2024-06	China
Transcatheter Self-expandable Valve Implantation for the Treatment of Severe Native Aortic Regurgitation NCT04864145 · ClinicalTrials.gov ↗ · Aortic Valve Disease	Not applicable	Recruiting	2021-05	China
Clinical Study of Perioperative Sleep Disorders in Cardiac Surgery NCT06778811 · ClinicalTrials.gov ↗ · Sleep Wake Disorders, Esketamine and the Quality of Recovery, Dexmedetomidine	Phase 4	Recruiting	2024-10	China
Transoral Nasal Cannula Oxygen Therapy for Mouth-Breathing Patients in the Postanesthesia Care Unit NCT07841223 · ClinicalTrials.gov ↗ · Postoperative Hypoxemia	Not applicable	Recruiting	2026-10	China
Circulating Non-coding RNA in Acute Ischemic Stroke With Endovascular Treatment (EVTRNA) NCT04230785 · ClinicalTrials.gov ↗ · Stroke, Acute, Stroke, Ischemic, Endovascular Treatment	Observational	Recruiting	2020-03	China
TAVR for Aortic Valve Disease NCT05439863 · ClinicalTrials.gov ↗ · Aortic Valve Disease	Observational	Recruiting	2022-07	China
Improving Blood Lipid Management in Symptomatic Intracranial Atherosclerotic Stenosis on Clinical Outcome NCT05397405 · ClinicalTrials.gov ↗ · Intracranial Artery Stenosis Drug: Biweekly	Not applicable	Recruiting	2022-05	China
Characteristics of Papez Loop Neural Network in T2DM （Type 2 Diabetes Mellitus） NCT06912321 · ClinicalTrials.gov ↗ · Type 2 Diabetes, Insulin Resistance, Cognitive Impairment	Observational	Recruiting	2024-05	China
Determination of the Optimal Volume of Liposomal Bupivacaine in Adductor Canal Block for Knee Joint Surgery NCT06942689 · ClinicalTrials.gov ↗ · Optimal Volume of Liposomal Bupivacaine	Phase 4	Recruiting	2025-06	China
Research on Optimal Diagnosis and Treatment of Cardiorenal Syndrome NCT05397392 · ClinicalTrials.gov ↗ · Heart Failure, Kidney Diseases, Kidney Injury	Observational	Recruiting	2016-01	China
Thyroid Cartilage Plane VS Superior Laryngeal Nerve Space Block in Awake Tracheal Intubation NCT07397234 · ClinicalTrials.gov ↗ · Superior Laryngeal Nerve Block	Not applicable	Recruiting	2026-02	China
The Effect of Remimazolam Tosylate on the Incidence of Postoperative Delirium in Older Patients Undergoing Cardiac Surgery: A Prospective Randomized Controlled Trial NCT07908121 · ClinicalTrials.gov ↗ · Delirium - Postoperative Drug: Propofol	Not applicable	Recruiting	2026-09	China
Analgesic Effects of Retro-superior Costotransverse Ligament Space Block for Video-assisted Thoracoscopic Surgery NCT07745881 · ClinicalTrials.gov ↗ · Nerve Block, Thoracoscopic Radical Resection of Lung Cancer	Not applicable	Recruiting	2026-08	China
The Survey of Treatment and Metabolic Status of Type 1 Diabetes Mellitus (T1DM). NCT06606509 · ClinicalTrials.gov ↗ · Type1 Diabetes Mellitus	Observational	Not yet open	2024-11	China, Japan
Biomarkers of Clopidogrel Resistance for Predicting Ischemic Recurrence After Cerebral Artery Stenting NCT07028775 · ClinicalTrials.gov ↗ · Ischemic Stroke	Observational	Not yet open	2025-06	China
The Diagnostic Application of PSMAPET/MR in Patients Undergoing Secondary Prostate Puncture NCT06901492 · ClinicalTrials.gov ↗ · PSMA PET/CT, Prostate Cancer, MpMRI	Not applicable	Not yet open	2025-06	China
Safety and Efficacy of DCB Therapy for ISR Under the Guidance of QFR (UNIQUE-DCB-II Study ) NCT04119986 · ClinicalTrials.gov ↗ · Coronary Heart Disease	Not applicable	Not yet open	2026-01	China
STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism NCT07603700 · ClinicalTrials.gov ↗ · Pulmonary Embolism, Venous Thromboembolism Drugs: Apixaban, Dabigatran, Edoxaban	Observational	Not yet open	2026-06	China
Radiolabeled TSPO Targeted Molecular Probe in Alzheimer's Disease. NCT07105956 · ClinicalTrials.gov ↗ · Alzheimer's Disease (AD)	Observational	Not yet open	2025-09	China
Home-Based Supportive Care Program for NMIBC Patients Receiving Intravesical Perfusion: Construction and Preliminary Application NCT07781956 · ClinicalTrials.gov ↗ · Non-Muscle-Invasive Bladder Cancer (NMIBC)	Not applicable	Not yet open	2026-08	China
The Effect of Bupivacaine Liposome Preemptive Analgesia on Postoperative Pain and Delirium in Elderly Patients Undergoing Hip Fracture Surgery NCT07066111 · ClinicalTrials.gov ↗ · Postoperative Delirium Drugs: Bupivacaine liposome, Tramadol	Phase 4	Not yet open	2025-07	China
Clinical Efficacy and Safety of Jingfang Granules in Treating Diarrhea-Predominant Irritable Bowel Syndrome With Cold-Dampness Disturbing Spleen Syndrome NCT07688161 · ClinicalTrials.gov ↗ · Diarrhea-predominant Irritable Bowel Syndrome	Phase 3	Not yet open	2026-07	China
Open Versus Fully Endoscopic Calcaneoplasty With Achilles Tendon Insertional Reconstruction for Haglund Syndrome NCT07887165 · ClinicalTrials.gov ↗ · Haglund Syndrome, Insertional Achilles Tendinopathy	Observational	Not yet open	2026-11	China
Vascular Aging and Acute Kidney Injury After Cardiac Surgery NCT07727772 · ClinicalTrials.gov ↗ · Acute Kidney Injury Cardiac Surgery, Postoperative Complications, Vascular Aging	Observational	Not yet open	2026-07	China
PCI With GDMT Versus GDMT Alone for Patients With Ischemic Cardiomyopathy and Reduced LVEF NCT07349979 · ClinicalTrials.gov ↗ · Heart Failure With Reduced Ejection Fraction, Coronary Artery Disease, Stable GDMT Drug: GDMT	Not applicable	Not yet open	2026-12	China
Safety and Efficacy of DCB Therapy for de Novo Lesions Under the Guidance of QFR in CHD Patients (UNIQUE-DCB-I Study ) NCT04104854 · ClinicalTrials.gov ↗ · Coronary Heart Disease	Not applicable	Not yet open	2026-01	China
Corheart 6 LVAS Long-term Follow-up Study NCT06267612 · ClinicalTrials.gov ↗ · Heart Failure	Not applicable	Not yet open	2024-02	China
Ultrasound-guided Non-invasive Simulation in Anesthesia Residency Training NCT07385885 · ClinicalTrials.gov ↗ · Ultrasound, Needle, Residency	Not applicable	Not yet open	2026-02	China
Effects of Tirzepatide on Gut Microbiota and Gastrointestinal Function After Drug Withdrawal in Obese Patients NCT07847515 · ClinicalTrials.gov ↗ · Obesity / Overweight Drug: Tirzepatide	Observational	Not yet open	2027-02	China
Pulmonary Artery Denervation for Heart Failure With Preserved Left Ventricular Ejection Fraction NCT07331220 · ClinicalTrials.gov ↗ · Heart Failure With Preserved Ejection Fraction Drug: GDMT	Not applicable	Not yet open	2026-12	China
Clinical Evaluation and Study of the Efficacy of a Centella Asiatica-Infused Facial Mask on Discosmetic Dermatosis NCT06763367 · ClinicalTrials.gov ↗ · Rosacea, Acne, Centella	Not applicable	Not yet open	2025-01	China
Effect of Liposomal Bupivacaine and Bupivacaine Hydrochloride for Superior Trunk Block of the Interscalene Brachial Plexus on Postoperative Diaphragmatic Function and Analgesia NCT07587203 · ClinicalTrials.gov ↗ · Proximal Humerus Surgery, Rotator Cuff Surgery, Shoulder Arthroplasty Drugs: Bupivacaine Hydrochloride, Liposomal bupivacaine	Not applicable	By invitation	2026-06	China
Application of Pericapsular Nerve Group (PENG) Block NCT07078773 · ClinicalTrials.gov ↗ · TURBT	Not applicable	Active, closed	2025-07	China
IVUS-guided DK Crush Stenting Technique for Patients With Complex Bifurcation Lesions NCT03770650 · ClinicalTrials.gov ↗ · Coronary Artery Disease	Not applicable	Active, closed	2018-12	China
Predictors and Clinical Outcomes of Patients With Coronary Heart Disease Co-morbid Depression Post Percutaneous Coronary Intervention NCT03852082 · Coronary Heart Disease, Percutaneous Coronary Intervention, Depression	Observational	Active, closed	2019-08	China
Effects of Neuromuscular Electrical Stimulation Combined With Ultrasound on Stroke Patients With Sarcopenia NCT07708597 · ClinicalTrials.gov ↗ · Stroke, Sarcopenia	Not applicable	Active, closed	2025-05	China
The Study of Postoperative Delirium and Glymphatic System Function in Cardiac Surgery NCT06901479 · ClinicalTrials.gov ↗ · Postoperative Delirium (POD)	Observational	Active, closed	2025-03	China
Research on Precision Pharmaceutical Care for Heart Transplant Recipients NCT06326775 · ClinicalTrials.gov ↗ · Heart Transplant Patients	Observational	Active, closed	2024-03	China
PCSK 9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With ACS After PCI NCT05457582 · ClinicalTrials.gov ↗ · Acute Coronary Syndrome, Hyperlipidemias, Percutaneous Coronary Intervention Drug: High-intensity statin	Not applicable	Active, closed	2023-03	China
AI-CCTA for Predicting Cardiovascular Events in CAD NCT07832175 · ClinicalTrials.gov ↗ · Coronary Artery Disease, Atherosclerotic Cardiovascular Disease	Observational	Active, closed	2026-06	China
Correlation of Preoperative Indices (serum Vit D, Calcium, Phosphorus, FAR, PLR, SII) on Intraoperative Bleeding in CRS NCT06737198 · ClinicalTrials.gov ↗ · Chronic Rhinosinusitis (CRS) with and Without Nasal Polyps	Observational	Active, closed	2024-11	China
Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions NCT04242134 · ClinicalTrials.gov ↗ · Coronary Artery Disease	Not applicable	Active, closed	2020-09	China
1-month vs 12-month DAPT for ACS Patients Who Underwent PCI Stratified by IVUS: IVUS-ACS and ULTIMATE-DAPT Trials NCT03971500 · ClinicalTrials.gov ↗ · Coronary Artery Disease Drugs: Aspirin, Ticagrelor	Not applicable	Active, closed	2019-08	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Nanjing First Hospital, Nanjing Medical University trials

30 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Conditions in Nanjing First Hospital, Nanjing Medical University trials

118 conditions

Coronary Artery Disease10 Ischemic Stroke3PCI3Coronary Heart Disease3Intracranial Artery Stenosis2Percutaneous Coronary Intervention2Hypoxia2Nerve Block2Type 2 Diabetes Mellitus2 Heart Failure2 Aortic Valve Disease2Type1 Diabetes Mellitus1Bone Lesion1Cartilage Degeneration1Osteo Arthritis Knee1Bone Fracture1Neuroblastoma1Pheochromocytoma1Paraganglioma1TURBT1Lung Cancers1Pancreatic Cancer1 Neuroendocrine Tumors1 Thyroid Cancer1

By trial register

Register	Trials	Recruiting
Clinical trials in China	74	44
Clinical trials in Japan	2	1

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Coronary Artery Disease

Sponsor	Trials
Fundación EPIC	15
China National Center for Cardiovascular Diseases	13
Seung-Jung Park	12
Samsung Medical Center	12
Yonsei University	11
Second Affiliated Hospital, Zhejiang University, School of Medicine	9
Shanghai Zhongshan Hospital	7
Ottawa Heart Institute Research Corporation	6
Xijing Hospital	6
Copenhagen University Hospital, Rigshospitalet	5

Sponsors with the most current trials registered for this condition.

Questions about Nanjing First Hospital, Nanjing Medical University trials

How many clinical trials does Nanjing First Hospital, Nanjing Medical University sponsor?

Nanjing First Hospital, Nanjing Medical University is the lead sponsor of 74 current trials on ClinicalTrials.gov in our China and Japan registers, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.

Are Nanjing First Hospital, Nanjing Medical University trials recruiting?

Yes. 44 of its 74 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Nanjing First Hospital, Nanjing Medical University testing?

Its current trials name 30 drugs and biologicals as interventions. The most frequent are GDMT (2), Recombinant Human Thyroid Stimulating Hormone (2), Tirzepatide (2), Amoxicillin (1) and Apixaban (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.